Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: triacetin; purified talc; hyprolose; isopropyl alcohol; lactose monohydrate; mannitol; titanium dioxide; magnesium stearate; purified water; pectin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlo 5 tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlo 5 tablets are indicated for the first line treatment of chronic stable angina. amlo 5 tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: iron oxide red; hypromellose phthalate; magnesium stearate; diacetylated monoglycerides; magnesium oxide; purified talc; mannitol; titanium dioxide; carnauba wax; ethylcellulose; hyprolose; butan-1-ol; shellac; ethanol absolute; iron oxide black - symptomatic relief of heartburn and other symptoms of gastro-oesophageal reflux disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated vegetable oil; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; strong ammonia solution; ethanol - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlodipine gh tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine gh tablets are indicated for the first line treatment of chronic stable angina. amlodipine gh tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 21.78 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 5.445 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: hypromellose phthalate; purified water; titanium dioxide; ethanol absolute; light magnesium oxide; magnesium stearate; diacetylated monoglycerides; iron oxide yellow; carnauba wax; hyprolose; ethylcellulose; purified talc; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hyprolose; iron oxide yellow; ethanol absolute; purified water; diacetylated monoglycerides; magnesium stearate; light magnesium oxide; hypromellose phthalate; ethylcellulose; titanium dioxide; carnauba wax; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.